Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial (NCT00960440) looked at a medicine called CP-690,550 (tested at two dose levels — 5 mg and 10 mg) compared to a dummy treatment (placebo) in people with rheumatoid arthritis. A total of 399 people took part across four groups: 133 received the 5 mg dose, 134 received the 10 mg dose, and 132 received placebo (some of whom later switched to one of the active doses). The trial measured three main things at the 3-month mark: the proportion of participants whose joint tenderness, swelling, pain and other arthritis-related measures improved by at least 20% (called an ACR20 response); how much difficulty participants had with everyday tasks like dressing, eating and walking (scored on a scale of 0 to 3, where 0 means no difficulty); and the proportion of participants whose overall disease activity score fell into a range considered to indicate remission. The reported data shows that at 3 months, approximately 42% of participants in the 5 mg group and 48% in the 10 mg group met the ACR20 improvement threshold, compared with around 24% in the placebo group. For everyday physical tasks, the average difficulty score at the start of the trial was about 1.60 (5 mg group), 1.50 (10 mg group), and 1.63 (placebo group). By 3 months, the reported average change from that starting score was a reduction of 0.41 points in both active-dose groups, compared with a reduction of 0.17 points in the placebo group. Regarding remission-level disease activity scores, approximately 7% of the 5 mg group and 11% of the 10 mg group reached that threshold, versus about 2% of the placebo group. The reported data also shows results at earlier and later time points. At 2 weeks, around 28% (5 mg) and 33% (10 mg) met the ACR20 threshold, compared with 17% on placebo. A stricter measure — at least 50% improvement (ACR50) — was reported in roughly 27% of both active-dose groups at 3 months, compared with about 8% on placebo. At 6 months, after placebo participants had switched to an active dose, ACR20 response rates across all groups ranged from approximately 40% to 55%, though the reported data does not allow a direct comparison with placebo at those later time points. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39192350) ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.